Canaccord Genuity Group Begins Coverage on Hims & Hers Health (NYSE:HIMS)

Canaccord Genuity Group started coverage on shares of Hims & Hers Health (NYSE:HIMS) in a report issued on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Truist Financial raised their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a report on Tuesday, February 27th. SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a market perform rating and a $10.00 target price for the company. Piper Sandler raised their target price on shares of Hims & Hers Health from $9.00 to $11.00 and gave the company a neutral rating in a report on Tuesday, February 27th. TheStreet upgraded shares of Hims & Hers Health from a d rating to a c rating in a report on Monday, March 4th. Finally, Leerink Partnrs restated a market perform rating on shares of Hims & Hers Health in a report on Monday, February 26th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $14.83.

Hims & Hers Health Trading Down 4.3 %

Shares of HIMS opened at $13.97 on Wednesday. The company has a 50-day simple moving average of $13.20 and a 200-day simple moving average of $9.62. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business’s revenue was up 47.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) EPS. As a group, research analysts anticipate that Hims & Hers Health will post 0.1 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 22,839 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 22,839 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $9.01, for a total transaction of $136,051.00. Following the completion of the sale, the chief executive officer now directly owns 51,653 shares in the company, valued at $465,393.53. The disclosure for this sale can be found here. Insiders have sold 673,335 shares of company stock valued at $8,452,208 in the last ninety days. Insiders own 31.63% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. Swiss National Bank grew its holdings in Hims & Hers Health by 7.9% in the first quarter. Swiss National Bank now owns 185,000 shares of the company’s stock valued at $986,000 after purchasing an additional 13,500 shares during the period. Citigroup Inc. grew its holdings in Hims & Hers Health by 249.9% in the first quarter. Citigroup Inc. now owns 34,718 shares of the company’s stock valued at $185,000 after purchasing an additional 24,796 shares during the period. Ergoteles LLC purchased a new stake in Hims & Hers Health in the first quarter valued at approximately $949,000. Charles Schwab Investment Management Inc. grew its holdings in Hims & Hers Health by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 616,214 shares of the company’s stock valued at $3,285,000 after purchasing an additional 14,990 shares during the period. Finally, Northern Trust Corp grew its stake in Hims & Hers Health by 1.3% during the first quarter. Northern Trust Corp now owns 253,307 shares of the company’s stock worth $1,350,000 after buying an additional 3,226 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.